• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> METHOD OF TREATMENT OF CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS

METHOD OF TREATMENT OF CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS

机译：治疗幽门螺杆菌和上皮性病毒-BARR病毒相关的慢性糜烂的方法

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used to treat chronic erosive gastritis associated with Helicobacter pylori (HP) and Epstein-Barr virus (EBV). Evaluate the results of determining the number of EBV copies in biopsy samples by the polymerase chain reaction method by 105 infiltrate cells. At the same time, the number of copies of EBV in the gastric mucosa is determined by the treatment regimen for chronic erosive gastritis associated with HP and EBV. This includes conduct anti-helicobacter therapy, the duration of which depends on the contamination of the gastric mucosa HP. Furthermore, prophylactic courses of treatment are carried out to prevent the exacerbation of the disease by administering the drug cycloferon 12.5 % in a dose of 2.0 ml intramuscularly. In this case, if the number of copies of EBV in the gastric mucosa is 10,000 by 105 and more infiltrate cells, the severity of chronic erosive gastritis is considered severe. In this case, against the background of anti-helicobacter therapy, cycloferon is administered simultaneously according to the scheme 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 days. Further, after 14 days, then after 6 and 12 months, repeated courses of administration of cycloferon are carried out according to the following scheme: 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28. If the number of copies of EBV in the gastric mucosa is from 1000 to 10,000 by 105 cell infiltration – the severity of the disease is regarded as average. In this case, against the background of anti-helicobacter therapy, cycloferon is administered according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29 days. Further, after 14 days, then after 6 months, the course of administration of cycloferon is repeated according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29 days. When the number of copies of EBV in the gastric mucosa from 100 to 1,000 by 105 infiltrate cells – diagnose mild severity of the disease. Treatment is carried out against the background of anti-helicobacter therapy by administering cycloferon according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 day, then to maintain the effect of 1 injection after 5 days 5 times. When the number of copies of EBV in the gastric mucosa doesn't exceed 100 to 105 infiltrate cells – the severity of chronic erosive gastritis is regarded as not requiring EBV treatment. In this case, cycloferon is administered according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 day once.;EFFECT: method provides a reduction in the frequency of exacerbations of the disease, the achievement of long-term clinical and endoscopic remission of the disease due to the individualization of the choice of means and the timing of treatment for a particular patient.;1 cl, 2 tbl, 3 ex
机译：技术领域本发明涉及医学，即涉及肠胃病，并且可以用于治疗与幽门螺杆菌（HP）和爱泼斯坦-巴尔病毒（EBV）相关的慢性糜烂性胃炎。评价通过10 5 浸润细胞的聚合酶链反应法确定活检样品中EBV拷贝数的结果。同时，胃粘膜中EBV的拷贝数由与HP和EBV相关的慢性糜烂性胃炎的治疗方案确定。这包括进行抗幽门螺杆菌治疗，其持续时间取决于胃粘膜HP的污染情况。此外，通过肌内注射剂量为2.0 ml的12.5％的环磷隆药物来进行预防性治疗，以预防疾病加重。在这种情况下，如果在胃粘膜中EBV的拷贝数乘以10 5 达到10,000，并且浸润细胞更多，则认为慢性糜烂性胃炎的严重性很严重。在这种情况下，在抗幽门螺杆菌治疗的背景下，根据方案1、2、4、6、8、10、12、14、16、18、20、22、24、26、28同时施用环feron天。此外，在14天之后，再在6个月和12个月之后，根据以下方案重复施用环铁素：1、2、4、6、8、10、12、14、16、18、20， 22、24、26、28。如果通过10 5 细胞浸润，胃粘膜中EBV的拷贝数为1000至10,000，则该疾病的严重程度视为平均。在这种情况下，在抗幽门螺杆菌治疗的背景下，根据方案1、2、4、6、8、11、14、17、20、23、26、29天施用环feron。此外，在14天后，然后在6个月后，根据方案1、2、4、6、8、11、14、17、20、23、26、29天重复给予环铁素的过程。当10 5 浸润细胞中的胃粘膜EBV拷贝数从100增加到1,000时–诊断该病轻度。在抗幽门螺杆菌治疗的背景下进行治疗，方法是按照方案1、2、4、6、8、11、14、17、20、23天给药环铁素，然后在5天后保持1次注射的效果天5次。当胃粘膜中EBV的拷贝数不超过100至10 5 浸润细胞时–慢性糜烂性胃炎的严重程度被认为不需要EBV治疗。在这种情况下，根据方案1、2、4、6、8、11、14、17、20、23天一次给予环feron。效果：该方法可降低疾病加重的频率，通过针对特定患者的手段选择和治疗时机的个性化，实现疾病的长期临床和内镜下缓解; 1 cl，2 tbl，3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号